Business
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
Thursday, January 7, 2021 at 4:15 pm ET BEVERLY HILLS, Calif., Jan. 4, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"Thursday, January 7, 2021 at 4:15 pm ET\n\n\nBEVERLY HILLS, Calif., Jan. 4, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform announces that it will be holding a shareholder update call on Thursday, January 7, 2021.\nManagement will host the conference call on Thursday, January 7, 2021 at 4:15 pm Eastern Time, to review past events and provide an update on its clinical programs and corporate highlights. Following management's formal remarks, Anthony Cataldo, Chairman and Chief Executive Officer of GT Biopharma will answer submitted questions. Please email your questions prior to the call to [email protected].\nConference Call Information\nTo join the conference call, live via telephone, interested parties should dial 712-775-7031 approximately 10 minutes before the start of the call. Use confirmation number 576-591-822 followed by the pound sign (#).\nAbout GT Biopharma, Inc.\nGT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.\nFor additional information visit www.gtbiopharma.com \nForward-Looking Statements\nThis press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as \"believes\", \"hopes\", \"intends\", \"estimates\", \"expects\", \"projects\", \"plans\", \"anticipates\" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-lookin...